StreetInsider.com News Articles

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

Thu, 22 Oct 2026 08:45:00 -0400

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 27, 2026, at 10:30 AM ET. To register, click here.

The event will feature nephrology leader and researcher Katherine Tuttle, MD, who will join Company management to discuss new insights into rilparencel’s mechanism of action from research presented at the American Society of Nephrology (ASN) Kidney Week

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

Thu, 22 Oct 2026 08:45:00 -0400

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Thu, 22 Oct 2026 08:00:00 -0400

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel
One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Thu, 22 Oct 2026 08:00:00 -0400

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel
One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Fri, 02 Oct 2026 09:00:00 -0400

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel
One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus

WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

Fri, 02 Oct 2026 09:00:00 -0400

Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel
One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus

Form 4 PROKIDNEY CORP. For: Aug 18 Filed by: Pereira Brian JG

Thu, 20 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260820/26957069.html

Form 4 PROKIDNEY CORP. For: Aug 18 Filed by: Pereira Brian JG

Thu, 20 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260820/26957069.html

Form 144 PROKIDNEY CORP. Filed by: Pereira Brian JG

Tue, 18 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260818/26945000.html

Form 144 PROKIDNEY CORP. Filed by: Pereira Brian JG

Tue, 18 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260818/26945000.html

Form 144 PROKIDNEY CORP. Filed by: Pereira Brian JG

Tue, 18 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260818/26944984.html

Form 144 PROKIDNEY CORP. Filed by: Pereira Brian JG

Tue, 18 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260818/26944984.html

Form SCHEDULE 13G/A PROKIDNEY CORP. Filed by: MORGAN STANLEY

Wed, 12 Aug 2026 15:45:00 -0400

si-local-file:///var/storage/secattach/20260812/26912430.html

Form SCHEDULE 13G/A PROKIDNEY CORP. Filed by: MORGAN STANLEY

Wed, 12 Aug 2026 15:45:00 -0400

si-local-file:///var/storage/secattach/20260812/26912430.html

ProKidney Corp (PROK) Misses Q2 EPS by 1c

Mon, 10 Aug 2026 17:38:34 -0400

ProKidney Corp (NASDAQ: PROK) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $129.75 thousand.

For earnings history and earnings-related data on ProKidney Corp (PROK) click here.

Form 8-K PROKIDNEY CORP. For: Aug 10

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898013.html

Form 8-K PROKIDNEY CORP. For: Aug 10

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898013.html

Form 10-Q PROKIDNEY CORP. For: Jun 30

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897977.html

Form 10-Q PROKIDNEY CORP. For: Jun 30

Mon, 10 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260810/26897977.html

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

Mon, 10 Aug 2026 16:05:00 -0400

Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027
On track for completion of full enrollment for PROACT 1 in the second half of 2026
Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experience
Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027